5-Hydroxytryptamine₃ receptor antagonists and cardiac side effects

Bibliography

• (FDA) USFaDA. FDA drug safety communication: updated information on 32 mg intravenous ondansetron (Zofran) dose and pre-mixed ondansetron products. 2012. Available from: www.fda.gov/Drugs/DrugSafety [Last accessed 11 May 2014]
   Google Scholar
• Gralla R. The evolution of antiemetic treatment. In: Mario A, Dicato M, editors. Medical management of Cancer treatment induced emesis. Martin Dunitz Ltd, Luxembourg; 1998
   Google Scholar
• Greene P. Drug utilization for antiemetic agents (serotonin 5-HT3 receptor antagonists). Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology 2012-1199.
   Google Scholar
• Grunberg SM, Gala KV, Lampenfeld M, et al. Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study. J Clin Oncol 1984;2:782-7
   PubMed Web of Science ®Google Scholar
• Gralla RJ, Itri LM, Pisko SE, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981;305:905-9
   PubMed Web of Science ®Google Scholar
• Kris MG, Gralla RJ, Tyson LB, et al. Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. Cancer 1985;55:527-34
   PubMed Web of Science ®Google Scholar
• Roila F, Tonato M, Basurto C, et al. Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1987;5:141-9
   PubMed Web of Science ®Google Scholar
• Costall B, Domeney AM, Naylor RJ, Tattersall FD. 5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology 1986;25:959-61
   PubMed Web of Science ®Google Scholar
• Fozard JR. Neuronal 5-HT receptors in the periphery. Neuropharmacology 1984;23:1473-86
   PubMed Web of Science ®Google Scholar
• Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxy-tryptamine M-receptor antagonism. Br J Pharmacol 1986;88:497-9
   PubMed Web of Science ®Google Scholar
• Cunningham D, Hawthorn J, Pople A, et al. Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet 1987;1(8548):1461-3
   PubMed Web of Science ®Google Scholar
• Gylys JA, Wright RN, Nicolosi WD, et al. BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties. J Pharmacol Exp Ther 1988;244:830-7
   PubMed Web of Science ®Google Scholar
• Butler A, Hill JM, Ireland SJ, et al. Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors. Br J Pharmacol 1988;94:397-412
   PubMed Web of Science ®Google Scholar
• Blower PR. The role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesis. Eur J Cancer 1990;26(Suppl 1):S8-S11
   PubMed Web of Science ®Google Scholar
• Graves T. Ondansetron: a new entity in emesis control. DICP 1990;24(Suppl 11):S51-4
   Google Scholar
• Leibundgut U, Lancranjan I. First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis. Lancet 1987;1(8543):1198
   PubMed Web of Science ®Google Scholar
• Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991;9:675-8
   PubMed Web of Science ®Google Scholar
• Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol – EASE. J Clin Oncol 2011;29(11):1495-501
   PubMed Web of Science ®Google Scholar
• Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-30
   PubMed Web of Science ®Google Scholar
• Herrstedt J. Are there differences between 5-HT3 receptor antagonists? In: Mario A, Dicato M, editors. Cancer treatment induced emesis. Martin Dunitz Ltd, London; 1998
   Google Scholar
• Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 2008;5:32-43
   PubMedGoogle Scholar
• Rojas C, Raje M, Tsukamoto T, Slusher B. Molecular mechanisms of 5HT3 and NK1 receptor antagonists in prevention of emesis. Eur J Pharmacol 2014;722:26-37
   PubMed Web of Science ®Google Scholar
• Seynaeve C, Schuller J, Buser K, et al. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group. Br J Cancer 1992;66:192-7
   PubMed Web of Science ®Google Scholar
• Couderc J, Xia J, Xu X, et al. Static and dynamic electrocardiographic patterns preceding torsades de pointes in the acquired and congenital long QT Syndrome. Comput Cardiol 2010;37:357-60
   Google Scholar
• Armahizer MJ, Seybert AL, Smithburger PL, Kane-Gill SL. Drug-drug interactions contributing to QT prolongation in cardiac intensive care units. J Crit Care 2013;28(3):243-9
   PubMed Web of Science ®Google Scholar
• Cubeddu LX. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther 2003;10:452-7
   PubMedGoogle Scholar
• Elming H, Brendorp B, Kober L, et al. QTc interval in the assessment of cardiac risk. Card Electrophysiol Rev 2002;6(3):289-94
   PubMedGoogle Scholar
• Garson A Jr. How to measure the QT interval--what is normal? Am J Cardiol 1993;72:14B-6B
   Web of Science ®Google Scholar
• Products CfPM. Points to Consider: the assessment of the potential fo rQT interval prolongation by non-cardiovascular medicinal products. The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, London: 1997
   Google Scholar
• Leotta G, Maule S, Rabbia F, et al. Relationship between QT interval and cardiovascular risk factors in healthy young subjects. J Hum Hypertens 2005;19:623-7
   PubMed Web of Science ®Google Scholar
• Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol 2006;47:362-7
   PubMed Web of Science ®Google Scholar
• Zumhagen S, Stallmeyer B, Friedrich C, et al. Inherited long QT syndrome: clinical manifestation, genetic diagnostics, and therapy. Herzschrittmacherther Elektrophysiol 2012;23:211-19
   PubMedGoogle Scholar
• Bartos DC, Giudicessi JR, Tester DJ, et al. A KCNQ1 mutation contributes to the concealed type 1 long QT phenotype by limiting the Kv7.1 channel conformational changes associated with protein kinase A phosphorylation. Heart Rhythm 2014;11:459-68
   PubMed Web of Science ®Google Scholar
• Shimizu W, Noda T, Takaki H, et al. Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. J Am Coll Cardiol 2003;41:633-42
   PubMed Web of Science ®Google Scholar
• Duhem C, Ries F, Dicato M. Side-effects of antiemetics. In: Dicato MA, editor. Medical management of cancer treatment induced emesis. Martin Dunitz Ltd, London; 1998. p. 221-8
   Google Scholar
• Patanwala AE, Amini R, Hays DP, Rosen P. Antiemetic therapy for nausea and vomiting in the emergency department. J Emerg Med 2010;39:330-6
   PubMed Web of Science ®Google Scholar
• Michalets EL, Smith LK, Van Tassel ED. Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction. Ann Pharmacother 1998;32:761-5
   PubMed Web of Science ®Google Scholar
• Armahizer MJ, Seybert AL, Smithburger PL, Kane-Gill SL. Drug-drug interactions contributing to QT prolongation in cardiac intensive care units. J Crit Care 2013;28:243-9
   PubMed Web of Science ®Google Scholar
• Composite list of all QTDrugs and the list of drugs to avoid for patients with congenital LQTS. Arizona Center for Education and Research on Therapeutics. 2014. Available from: http://crediblemeds.org/everyone/composite-list-all-qtdrugs/?rf=All [Last accessed 1 August 2014]
   Google Scholar
• Ellidokuz E, Kaya D. The effect of metoclopramide on QT dynamicity: double-blind, placebo-controlled, cross-over study in healthy male volunteers. Aliment Pharmacol Ther 2003;18:151-5
   PubMed Web of Science ®Google Scholar
• Kingwell B, van den Buuse M. Does metoclopramide increase sympathetic drive to the heart? Clin Auton Res 2003;13:242-4
   PubMed Web of Science ®Google Scholar
• Chou CC, Wu D. Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block. Chang Gung Med J 2001;24:805-9
   PubMedGoogle Scholar
• Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol 2007;102:2036-45
   PubMed Web of Science ®Google Scholar
• Doggrell SA, Hancox JC. Cardiac safety concerns for domperidone, an antiemetic and prokinetic, and galactogogue medicine. Expert Opin Drug Saf 2014;13:131-8
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Jeppesen BH, Dombernowsky P. Dose-limiting hypotension with the 5-HT3-receptor antagonist batanopride (BMY-25801). Ann Oncol 1991;2:154-5
   PubMed Web of Science ®Google Scholar
• Keller GA, Ponte ML, Di Girolamo G. Other drugs acting on nervous system associated with QT-interval prolongation. Curr Drug Saf 2010;5:105-11
   PubMedGoogle Scholar
• Kuryshev YA, Brown AM, Wang L, et al. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther 2000;295:614-20
   PubMed Web of Science ®Google Scholar
• Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother 2003;37(9):1276-86
   PubMed Web of Science ®Google Scholar
• Keefe DL. The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern? Oncologist 2002;7:65-72
   PubMed Web of Science ®Google Scholar
• Zofran® (ondansetron hydrochloride) tablets [package insert]. Research Triangle Park NG. 2010. Available from: http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=50002 [Last accessed 13 May 2014]
   Google Scholar
• Zofran® (ondansetron hydrochloride) injection for intravenous use [package insert]. Research Triangle Park NG. 2010. Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d9a71b42-ddfc-49d5-7280-0fc0041dba41 [Last accessed 13 May 2014]
   Google Scholar
• Kytril (granisetron hydrochloride) injection, for intravenous use [package insert]. South Genentech USA, Inc., San Francisco, CA; 2011. Available from: http://www.drugs.com/pro/kytril-injection.html [Last accessed 11 May 2014]
   Google Scholar
• Kytril (granisetron hydrochloride) tablets [package insert]. Roche Laboratories, Inc.,Nutley, NJ; 2010. Available from: http://www.drugs.com/pro/kytril.html [Last accessed 11 May 2014]
   Google Scholar
• Aloxi® (palonsetron HCl) injection for intravenous use [package insert]. Eisai, Inc., Woodcliff Lake, NJ; 2009. Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bd06f321-bb42-4748-92f3-d59626b540e0 [Last accessed 13 May 2014]
   Google Scholar
• Weissenburger J, Funck-Brentano C, Jaillon P, Charbit B. Droperidol and ondansetron in vitro electrophysiological drug interaction study. Fundam Clin Pharmacol 2009;23:719-26
   PubMed Web of Science ®Google Scholar
• Rouet R, Worou ME, Puddu PE, et al. Nifedipine blocks ondansetron electrophysiological effects in rabbit purkinje fibers and decreases early after depolarization incidence. Curr Clin Pharmacol 2012;7:41-8
   PubMedGoogle Scholar
• Benedict CR, Arbogast R, Martin L, et al. Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol 1996;28:53-9
   PubMed Web of Science ®Google Scholar
• Boike SC, Ilson B, Zariffa N, Jorkasky DK. Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am J Health Syst Pharm 1997;54:1172-6
   PubMed Web of Science ®Google Scholar
• Charbit B, Alvarez JC, Dasque E, et al. Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study. Anesthesiology 2008;109:206-12
   PubMed Web of Science ®Google Scholar
• Chan MT, Choi KC, Gin T, et al. The additive interactions between ondansetron and droperidol for preventing postoperative nausea and vomiting. Anesth Analg 2006;103:1155-62
   PubMed Web of Science ®Google Scholar
• Gupta SD, Pal R, Sarkar A, et al. Evaluation of Ondansetron-induced QT interval prolongation in the prophylaxis of postoperative emesis. J Nat Sci Biol Med 2011;2:119-24
   PubMedGoogle Scholar
• Ganjare A, Kulkarni AP. Comparative electrocardiographic effects of intravenous ondansetron and granisetron in patients undergoing surgery for carcinoma breast: a prospective single-blind randomised trial. Indian J Anaesth 2013;57:41-5
   PubMedGoogle Scholar
• Charbit B, Albaladejo P, Funck-Brentano C, et al. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology 2005;102:1094-100
   PubMed Web of Science ®Google Scholar
• Hesketh P, Navari R, Grote T, et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol 1996;14:2242-9
   PubMed Web of Science ®Google Scholar
• Lofters WS, Pater JL, Zee B, et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 1997;15:2966-73
   PubMed Web of Science ®Google Scholar
• Baltzer L. Reversible electrocardiographic interval prolongations following the specific serotonin antagnists ondansetron (OND) and dolastron mesylate (DM): a possible drug class effect without sequelae? Proc Am Soc Clin Oncol 1994;13:433a
   Google Scholar
• Havrilla PL, Kane-Gill SL, Verrico MM, et al. Coronary vasospasm and atrial fibrillation associated with ondansetron therapy. Ann Pharmacother 2009;43(3):532-6
   PubMed Web of Science ®Google Scholar
• Kasinath NS, Malak O, Tetzlaff J. Atrial fibrillation after ondansetron for the prevention and treatment of postoperative nausea and vomiting: a case report. Can J Anaesth 2003;50:229-31
   PubMed Web of Science ®Google Scholar
• Salvucci AA, Squire B, Burdick M, et al. Ondansetron is safe and effective for prehospital treatment of nausea and vomiting by paramedics. Prehosp Emerg Care 2011;15:34-8
   PubMed Web of Science ®Google Scholar
• Buyukavci M, Olgun H, Ceviz N. The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. Am J Clin Oncol 2005;28:201-4
   PubMed Web of Science ®Google Scholar
• Mason JW, Selness DS, Moon TE, et al. Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron. Clin Cancer Res 2012;18:2913-21
   PubMed Web of Science ®Google Scholar
• Watanabe H, Hasegawa A, Shinozaki T, et al. Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Cancer Chemother Pharmacol 1995;35:278-82
   PubMed Web of Science ®Google Scholar
• Jantunen IT, Kataja VV, Muhonen TT, Parviainen T. Effects of granisetron with doxorubicin or epirubicin on ECG intervals. Cancer Chemother Pharmacol 1996;37:502-4
   PubMed Web of Science ®Google Scholar
• Carmichael J, Philip PA, Forfar C, Harris AL. An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease. Cancer Chemother Pharmacol 1995;37:134-8
   PubMed Web of Science ®Google Scholar
• Carmichael J, Harris A. High-dose i.v. granisetron for the prevention of chemotherapy-induced emesis: cardiac safety and tolerability. Anticancer Drugs 2003;14:739-44
   PubMed Web of Science ®Google Scholar
• Pinarli FG, Elli M, Dagdemir A, et al. Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children. Pediatr Blood Cancer 2006;47:567-71
   PubMed Web of Science ®Google Scholar
• Boccia RV, Gordan LN, Clark G, et al. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer 2011;19:1609-17
   PubMed Web of Science ®Google Scholar
• Cakir FB, Yapar O, Canpolat C, et al. Cardiac effects of granisetron in a prospective crossover randomized dose comparison trial. Support Care Cancer 2012;20:2451-7
   PubMed Web of Science ®Google Scholar
• Balki M, Kasodekar S, Dhumne S, Carvalho JC. Prophylactic [corrected] granisetron does not prevent postdelivery nausea and vomiting during elective cesarean delivery under spinal anesthesia. Anesth Analg 2007;104:679-83
   PubMed Web of Science ®Google Scholar
• Rojas C, Slusher BS. Pharmacological mechanisms of 5-HT(3) and tachykinin NK(1) receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol 2012;684:1-7
   PubMed Web of Science ®Google Scholar
• Eisenberg P, MacKintosh FR, Ritch P, et al. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol 2004;15:330-7
   PubMed Web of Science ®Google Scholar
• MGI Pharma I. Aloxi (palanosetron, HCl) injection prescribing information. MGI, Bloomington, MN, USA: 2003
   Google Scholar
• Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003;98:2473-82
   PubMed Web of Science ®Google Scholar
• Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570-7
   PubMed Web of Science ®Google Scholar
• Decker GM, DeMeyer ES, Kisko DL. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol 2006;4:35-41, 52
   PubMedGoogle Scholar
• Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441-9
   PubMed Web of Science ®Google Scholar
• Hunt TL, Gallagher SC, Cullen MT Jr, Shah AK. Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects. J Clin Pharmacol 2005;45:589-96
   PubMed Web of Science ®Google Scholar
• Yavas C, Dogan U, Yavas G, et al. Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study. Support Care Cancer 2012;20:2343-7
   PubMed Web of Science ®Google Scholar
• Gonullu G, Demircan S, Demirag MK, et al. Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer 2012;20:1435-9
   PubMed Web of Science ®Google Scholar
• Dogan U, Yavas G, Tekinalp M, et al. Evaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarization. Eur Rev Med Pharmacol Sci 2012;16:462-8
   PubMed Web of Science ®Google Scholar
• Aogi K, Sakai H, Yoshizawa H, et al. A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy. Support Care Cancer 2012;20:1507-14
   PubMed Web of Science ®Google Scholar
• Min JJ, Yoo Y, Kim TK, Lee J-M. Intravenous palonosetron increases the incidence of QTC prolongation during sevoflurane general anesthesia for lararotomy. Korean J Anesthesiol 2013;65:397-402
   PubMedGoogle Scholar
• Kim HJ, Lee H-C, Jung YS, et al. Effect of palonosetron on the QTc interval in patients undergoing sevoflurane anaesthesia. Br J Anaesth 2014;112:460-8
   PubMed Web of Science ®Google Scholar
• Jorgensen TL, Herrstedt J, Friis S, Hallas J. Polypharmacy and drug use in elderly Danish cancer patients during 1996 to 2006. J Geriatric Oncol 2012;3:33-40
   Web of Science ®Google Scholar
• Hafermann MJ, Namdar R, Seibold GE, Page RL II. Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study. Drug Healthc Patient Saf 2011;3:53-8
   PubMedGoogle Scholar
• Tisdale JE, Wroblewski HA, Overholser BR, et al. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US. Drug Saf 2012;35:459-70
   PubMed Web of Science ®Google Scholar
• Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 2013;6:479-87
   PubMed Web of Science ®Google Scholar
• Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998;25(Suppl 10):72-85
   PubMedGoogle Scholar
• Hochster H, Wasserheit C, Speyer J. Cardiotoxicity and cardioprotection during chemotherapy. Curr Opin Oncol 1995;7:304-9
   PubMedGoogle Scholar
• Lewis C. A review of the use of chemoprotectants in cancer chemotherapy. Drug Saf 1994;11:153-62
   PubMed Web of Science ®Google Scholar
• Ryberg M, Nielsen D, Skovsgaard T, et al. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998;16:3502-8
   PubMed Web of Science ®Google Scholar
• Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672-7
   PubMed Web of Science ®Google Scholar
• Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900-5
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991;9:1704-12
   PubMed Web of Science ®Google Scholar
• Menard O, Martinet Y, Lamy P. Cisplatin-induced atrial fibrillation. J Clin Oncol 1991;9:192-3
   PubMed Web of Science ®Google Scholar
• Freeman NJ, Costanza ME. 5-Fluorouracil-associated cardiotoxicity. Cancer 1988;61:36-45
   PubMed Web of Science ®Google Scholar
• Keefe DL, Roistacher N, Pierri MK. Clinical cardiotoxicity of 5-fluorouracil. J Clin Pharmacol 1993;33:1060-70
   PubMed Web of Science ®Google Scholar
• Braverman AC, Antin JH, Plappert MT, et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991;9:1215-23
   PubMed Web of Science ®Google Scholar
• Bolis G, Scarfone G, Zanaboni F, et al. A phase I-II trial of fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer. Eur J Cancer 1997;33:592-5
   PubMed Web of Science ®Google Scholar
• Oppenheim MH, Lotze MT. Interleukin-2: solid-tumor therapy. Oncology 1994;51:154-69
   PubMed Web of Science ®Google Scholar
• Scher KS, Hurria A. Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol 2012;30:2036-8
   PubMed Web of Science ®Google Scholar
• Nordic database. 2014. Available from: http://www-dep.iarc.fr/NORDCAN/DK/frame.asp [Last accessed 15 May 2014]
   Google Scholar
• Kleiman RB, Shah RR, Morganroth J, Replacing the Thorough QT. Study: reflections of a baby in the bath water. Br J Clin Pharmacol 2014;78(2):195-201
   PubMed Web of Science ®Google Scholar
• Shah RR, Morganroth J. ICH E14 Q & A (R1) document: perspectives on the updated recommendations on thorough QT studies. Br J Clin Pharmacol 2013;75:959-65
   PubMed Web of Science ®Google Scholar
• Morganroth J, Shah RR, Scott JW. Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc interval). Clin Pharmacol Ther 2010;87:166-74
   PubMed Web of Science ®Google Scholar
• Simpson KH, Hicks FM. Clinical pharmacokinetics of ondansetron. A review. J Pharm Pharmacol 1996;48:774-81
   PubMed Web of Science ®Google Scholar
• Hsyu PH, Pritchard JF, Bozigian HP, et al. Comparison of the pharmacokinetics of an ondansetron solution (8 mg) when administered intravenously, orally, to the colon, and to the rectum. Pharm Res 1994;11:156-9
   PubMed Web of Science ®Google Scholar
• Wolf H. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists. Scand J Rheumatol 2000;113(Suppl):37-45
   Google Scholar
• Howell J, Smeets J, Drenth HJ, Gill D. Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting. J Oncol Pharm Pract 2009;15:223-31
   PubMedGoogle Scholar
• Yang LP, Scott LJ. Palonosetron: in the prevention of nausea and vomiting. Drugs 2009;69:2257-78
   PubMed Web of Science ®Google Scholar
• Audhuy B, Cappelaere P, Martin M, et al. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 1996;32A:807-13
   PubMed Web of Science ®Google Scholar